Prognostic factors for patients with relapsed or refractory multiple myeloma who are initiating a fourth or later line car T-cell or bispecific antibody therapy: a systematic literature review and meta-analysis.
Expert Rev HematolJun 22, 2026 (epub)
Krina Patel, Ken Hasegawa, Jie Ting et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic literature review and meta-analysis evaluated prognostic factors for patients with relapsed or refractory multiple myeloma undergoing fourth or later line CAR T-cell or bispecific antibody therapy. The analysis included 15 significant factors, revealing that age, cytogenetic risk, and ECOG performance status, among others, influence treatment outcomes. Notably, associations varied by treatment class.
Key findings
- Age, cytogenetic risk, and ECOG performance status were identified as significant prognostic factors.
- Prior anti-BCMA exposure and triple-class refractory status also influenced treatment outcomes.
- Associations between prognostic factors and outcomes varied by treatment class.
Why it matters
Understanding prognostic factors in multiple myeloma can guide clinicians in making informed treatment decisions and improve patient management strategies, particularly in later lines of therapy.